– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –  

– These two peptides have attracted growing scientific interest for their potential neuroprotective and cognitive-supportive properties –

– Collaboration represents a significant step toward making precision cognitive care more measurable, scalable, and clinically actionable –  

KENMORE, N.Y. and LOS ANGELES, July 28, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, and Next Health, a global leader in health optimization and longevity, today announced a strategic partnership to launch a novel precision cognitive health platform integrating Firefly’s AI-powered, U.S. Food and Drug Administration ("FDA")-cleared EEG/ERP brain biomarker technology with personalized cognitive peptide protocols. The initiative aims to provide physicians with objective measures of brain function to help personalize, monitor, and optimize emerging cognitive therapies.

The announcement follows last week's recommendation by an FDA Advisory Committee to add six therapeutic peptides—including Epitalon and Semax—to the list of bulk drug substances eligible for pharmacy compounding. While the recommendation is not binding and requires further FDA action, it represents an important regulatory milestone that could broaden physician access to these emerging peptide therapies.1

Epitalon and Semax have each drawn growing attention in the scientific literature for their potential neuroprotective and cognitive-supportive properties. While additional clinical research remains ongoing, both peptides have been studied for potential applications in the evolving field of precision cognitive medicine.2,3

By combining objective EEG-based biomarkers with personalized therapeutic protocols, the collaboration seeks to replace subjective assessments of cognitive health with data-driven clinical decision-making. The collaboration establishes a scalable framework for integrating objective brain biomarker assessments into routine longevity and cognitive care, helping lay the foundation for broader adoption of quantitative neurodiagnostics in precision medicine.